Provided by Tiger Trade Technology Pte. Ltd.

Caprice Resources

0.088
+0.0044.76%
Volume:3.62M
Turnover:308.64K
Market Cap:76.69M
PE:-21.39
High:0.088
Open:0.084
Low:0.083
Close:0.084
52wk High:0.160
52wk Low:0.066
Shares:871.44M
Float Shares:644.73M
Volume Ratio:0.44
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.004
EPS(LYR):-0.008
ROE:-12.20%
ROA:-7.58%
PB:3.04
PE(LYR):-11.31

Loading ...

How Dividend Reaffirmation And Institutional Demand At Carpenter Technology (CRS) Has Changed Its Investment Story

Simply Wall St.
·
Apr 19

Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs

prnewswire
·
Apr 18

Southern Copper Corp Stock (SCCO) Moved Up by 3.81% on Apr 10: Drivers Behind the Movement

TradingKey
·
Apr 10

Is It Too Late To Consider Carpenter Technology (CRS) After Its 136% One Year Surge

Simply Wall St.
·
Apr 03

Assessing Carpenter Technology (CRS) Valuation After Strong Multi‑Year Shareholder Returns

Simply Wall St.
·
Mar 24

Caprice Resources Starts Multi-Rig Drilling Campaign in Western Australia; Shares Down 14%

MT Newswires Live
·
Mar 23

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

prnewswire
·
Mar 18

A Look At Carpenter Technology (CRS) Valuation After A Strong Multi Year Share Price Run

Simply Wall St.
·
Mar 16

BUZZ-Australia's Caprice Resources slides on discounted placement

Reuters
·
Mar 09

BRIEF-Caprice Resources To Raise A$12.74 Million Placement At A$0.08 Per Share

Reuters
·
Mar 09

Caprice Resources - to Raise a$12.74 Mln Placement at a$0.08 per Share

THOMSON REUTERS
·
Mar 09

BRIEF-Caprice Resources Requests Trading Halt

Reuters
·
Mar 06

Caprice Resources Ltd - Requests Trading Halt Pending Capital Raising Announcement

THOMSON REUTERS
·
Mar 06

Is Strong Q2 Beat And Higher Guidance Altering The Investment Case For Carpenter Technology (CRS)?

Simply Wall St.
·
Mar 04

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

prnewswire
·
Mar 04

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

prnewswire
·
Mar 02